Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDrreddyslaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy Dr Reddy's Laboratories, says Ashu Madan

      Ashu Madan of Religare Securities is of the view that one may buy Dr Reddy's Laboratories.

    • Stay invested in Dr Reddy's Laboratories, says Ashish Kyal

      Ashish Kyal of wavesstrategy.com is of the view that one may hold Dr Reddy's Laboratories.

    • Hold Dr Reddy's Lab; target Rs 3933: Mayuresh Joshi

      Mayuresh Joshi of Angel Broking is of the view that one may hold Dr Reddy's Laboratories with a target of Rs 3933 over the next 12-15 months.

    • Avoid Dr Reddy's Laboratories, says Prakash Diwan

      Prakash Diwan of prakashdiwan.in is of the view that one may avoid Dr Reddy's Laboratories.

    • Prefer Alembic Pharma; target Rs 750: Shahina Mukadam

      Shahina Mukadam, Independent Market Expert is of the view that one may prefer Alembic Pharmaceuticals and Dr Reddy's Laboratories.

    • Sell Dr Reddy's Laboratories on rise: Hemant Thukral

      According to Hemant Thukral of Aditya Birla Money, one may sell Dr Reddy's Laboratories on every rise.

    • Have cut Dr Reddy's target price to Rs 3250/sh: Phillip Cap

      Surya Narayan Patra of Phillip Capital says that it would take minimum one year for Dr. Reddy‘s Laboratories to resolve this issue.

    • Despite 3% rise, best to sell Dr Reddy's on Nexium woes?

      Brokerages are still cautious on the stock as troubles do not seem to end for the Indian pharma company.

    • Prefer RIL, SBI, Tata Motors: Deven Choksey

      Deven Choksey of KR Choksey Investment Managers is of the view that one may prefer State Bank of India, Reliance Industries and Tata Motors.

    • Add Dr Reddy's Lab in portfolio, says Deven Choksey

      Deven Choksey of KR Choksey Investment Managers is of the view that one may add Dr Reddy's Laboratories in the portfolio.

    • Enter Dr Reddy's Lab at around Rs 3250-3300: SP Tulsian

      SP Tulsian of sptulsian.com is of the view that one may enter Dr Reddy's Laboratories at around Rs 3250-3300.

    • Dr Reddy's Laboratories may go below Rs 3000: Sameet Chavan

      Sameet Chavan, Technical Analyst at Angel Broking is of the view that if Dr Reddy's Laboratories stays below Rs 3,250 then it is likely to go below Rs 3000.

    • Short Dr Reddy's Laboratories, says Aditya Agarwal

      Aditya Agarwal of Way2Wealth Securities advises shorting Dr Reddy's Laboratories.

    • Dr Reddy's Laboratories may slip to Rs 3250: Rajat Bose

      Rajat Bose of rajatkbose.com feels that Dr Reddy's Laboratories may slip to Rs 3250.

    • Hold Dr Reddy's Lab, says Vijay Chopra

      Vijay Chopra of enochventures.com is of the view that one may hold Dr Reddy's Laboratories.

    • Buy Dr Reddy's Laboratories, says SP Tulsian

      SP Tulsian of sptulsian.com is of the view that one may buy Dr Reddy's Laboratories.

    • See weakness in Indiabulls Housing: CA Rudramurthy BV

      CA Rudramurthy BV of Vachana Investments is of the view that one may see weakness in Indiabulls Housing Finance.

    • Buy Dr Reddy's Labs at around Rs 3200: Kunal Bothra

      Kunal Bothra of LKP Securities is of the view that one can look at buying Dr Reddy's Labs at around Rs 3200.

    • See downside in Dr Reddy's, enter around Rs 3300: MOST

      Shubham Agarwal of Motilal Oswal Securities is of the view that one may see downside in Dr Reddy's Labs and feels that one can re-enter the stock at around Rs 3300.

    • Enter Sun Pharma on dips: Ambareesh Baliga

      Ambareesh Baliga, Independent Market Expert is of the view that one can enter Sun Pharma on dips.

    • Bull's Eye: Sell Dr Reddy's, JSW Energy, Ceat, buy BoI

      Manas Jaiswal of manasjaiswal.com advises buying Bank of India with a target of Rs 142.

    • Keep Dr Reddy's in portfolio for long term: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can keep Dr Reddy's Labs in portfolio for long term.

    • Hold Dr Reddy's, Lupin, Sun Pharma in portfolio: Baliga

      Ambareesh Baliga, Independent Market Expert is of the view that one can keep Dr Reddy's Labs, Lupin and Sun Pharma in the portfolio from the pharma space.

    • ICICI Bank good bet, ITC should be de-rated: Sabharwal

      Sandip Sabharwal of asksandipsabharwal.com is of the view that ICICI Bank is a good bet and feels that ITC should be de-rated.

    • Look at Glenmark Pharma: Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that one may look at Glenmark Pharma.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347